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Abstract
Background: The true burden of reactivation of remote latent tuberculosis infection (reactivation TB) among foreign-born
persons with tuberculosis (TB) within the United States is not known. Our study objectives were to estimate the proportion
of foreign-born persons with TB due reactivation TB and to describe characteristics of foreign-born persons with
reactivation TB.
Methods: We conducted a cross-sectional study of patients with an M. tuberculosis isolate genotyped by the U.S. National TB
Genotyping Service, 2005–2009. TB cases were attributed to reactivation TB if they were not a member of a localized cluster
of cases. Localized clusters were determined by a spatial scan statistic of cases with isolates with matching TB genotype
results. Crude odds ratios and 95% confidence intervals were used to assess relations between reactivation TB and select
factors among foreign-born persons.
Main Results: Among the 36,860 cases with genotyping and surveillance data reported, 22,151 (60%) were foreign-born.
Among foreign-born persons with TB, 18,540 (83.7%) were attributed to reactivation TB. Reactivation TB among foreign-
born persons was associated with increasing age at arrival, incidence of TB in the country of origin, and decreased time in
the U.S. at the time of TB diagnosis.
Conclusions: Four out of five TB cases among foreign-born persons can be attributed to reactivation TB and present the
largest challenge to TB elimination in the U.S. TB control strategies among foreign-born persons should focus on finding
and treating latent tuberculosis infection prior to or shortly after arrival to the United States and on reducing the burden of
LTBI through improvements in global TB control.
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Introduction
In the United States, the proportion of reported tuberculosis
(TB) cases among foreign-born persons doubled from 29% in 1993
to 59% in 2009, concurrent with a 54% decrease in total TB cases
from 25,107 to 11,545 [1]. The TB incidence rate among foreign-
born persons, at 18.7 per 100,000 in 2009, is nearly ten times the
TB incidence among the U.S.-born population. These disparities
between U.S. and foreign-born persons have raised concerns
about the ability to further reduce, and eventually eliminate TB in
the United States [2,3]. Similar trends were observed in other low-
incidence countries globally [4–6], prompting the World Health
Organization to suggest that when the proportion of foreign-born
cases exceeds 70% of the national total of reported cases, no
greater than 2% decrease in annual TB incidence can be expected
without rethinking contemporary TB prevention and control
strategies [7].
There are three main TB control strategies: 1) finding and
treating patients with TB disease as quickly as possible, 2)
examining persons in close contact with a person diagnosed with
infectious TB disease, in order to diagnose and treat TB disease
and latent TB infection (LTBI), and 3) finding and treating people
with LTBI to prevent TB disease [8]. Although most TB among
the foreign-born has been attributed to reactivation of remotely
acquired tuberculosis infection, or reactivation TB (most likely
acquired in their country of origin), control measures to detect and
treat LTBI are not widely implemented [9,10]. Understanding the
epidemiology of reactivation TB will assist in planning TB control
efforts among foreign-born persons [11–13], without which the
goal of TB elimination will not be possible [3,12].
TB genotyping results, when combined with epidemiologic
data, may help identify recent TB transmission [14]. A basic
assumption of this approach is that recent TB transmission is
localized in place and time, that is, resulting from progression to
TB disease from an infection acquired a short time ago and in the
same location. Reactivation TB is a result of remotely acquired TB
infection that is generally associated with progression of disease
from an infection acquired in the past and often in another
location. Thus cases with TB genotypes that are not clustered in
time and space are often used as a marker of remotely acquired
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TB infection [14]. Researchers using TB genotyping have
reported that most cases among foreign-born persons are due to
the reactivation of remotely acquired TB infection occurring
before U.S. arrival [15–19]. However, these studies were small or
geographically limited.
In 2004, the U.S. Centers for Disease Control and Prevention
(CDC) initiated national TB genotyping surveillance to routinely
characterize at least one M. tuberculosis complex isolate from every
TB case in the United States [20]. Data collected from this system
offers a unique opportunity to describe the molecular epidemiol-
ogy of tuberculosis on a national level. The purpose of this analysis
is to estimate the proportion of tuberculosis in the United States
attributable to reactivation of remotely acquired TB infection and
to assess key factors associated with reactivation TB comparing
U.S. and foreign-born persons.
Methods
Study Design and Participants
We conducted a cross-sectional analysis of culture-confirmed
TB reported to the U.S. National Tuberculosis Surveillance
System (NTSS) by the 50 states and the District of Columbia from
January 2005 to December 2009. Clinical, demographic, and
epidemiologic variables for each case are collected for surveillance
purposes and are described elsewhere [1]. Consistent with U.S.
Census Bureau definitions, individuals were classified as foreign-
born if they were not born in the United States or an associated
jurisdiction, or if they were born in a foreign country and neither
parent was a U.S. citizen [21]. All others were classified as U.S.-
born.
M. tuberculosis complex isolates were characterized using a
standardized protocol for spacer oligonucleotide typing (spoligo-
typing) and using a panel of 12 mycobacterial interspersed
repetitive unit variable number of tandem repeats (MIRU–
VNTR) loci [22–24]. Genotyping results for each submitted
isolate were linked to NTSS case records by state and local TB
control programs using a standardized case identification number
[1] and a unique laboratory accession number to form discrete
individual isolate-case records [25]. Our final study population
included all reported culture-positive TB cases reported from
January 2005 to December 2009 with a complete spoligotype and
12-locus MIRU–VNTR result.
Genotype clusters were defined as at least 2 cases with matching
spoligotype and 12-locus MIRU-VNTR results reported within
statistically significant geospatial zones determined by a spatial
scan statistic as described elsewhere [26]. Briefly, three scans
comprised of 3-year overlapping intervals (Scan A: 2005–2007;
Scan B: 2006–2008; Scan C: 2007–2009) were performed to
identify spatial clusters occurring within a 3-year period. If cases
were identified as a member of a statistically significant spatial
cluster in any of the 3 periods, they were considered clustered.
There was no duplicative case counting. All cases that were not
genotypically and spatially clustered were considered reactivation
of remotely acquired TB infection, or reactivation TB.
Data Analysis
We used a Pearson’s chi-square statistic to assess differences in
proportions of reactivation TB between U.S. and foreign-born
persons. We calculated the proportions of foreign born cases
attributed to reactivation TB for each of the 25 countries that
contribute the largest proportions of reactivation TB. Crude odds
ratios and 95% confidence intervals were used to evaluate the
relationship between select factors (annual TB incidence in
country of origin, age at arrival in the U.S., and time in the
U.S. after arrival) and reactivation TB among foreign-born
persons.
We grouped the following continuous variables into three or
more ordinal categories: age at arrival in U.S., time since arrival in
U.S. to TB diagnosis, and TB incidence rate in country of origin.
Time since arrival was categorized as ,2 years, $2 years to ,5
years, and $5 years. These categories were chosen to reflect the
known risk of reactivation TB, which is highest in the first 2 years
after infection (or after high-intensity exposure has ended) with
rapid decline after 5 years [27–30]. TB incidence in a person’s
country of origin was categorized into three groups based on 2010
WHO estimates [31]: 150 or more cases per 100,000 population,
20 to 149 cases per 100,000, and less than 20 cases per 100,000.
Results
From 2005 to 2009, there were 65,529 new TB cases reported
to the NTSS, of which 51,015 (78%) were culture-confirmed.
Genotype and country of origin were available for 72% of all new
culture-confirmed TB cases, providing a study sample of 36,860
cases; 22,151 (60.3%) among foreign-born persons and 14,594
(39.7%) among U.S.-born persons (Figure 1). A significantly higher
proportion of TB cases were attributed to reactivation TB among
foreign-born persons compared to U.S. born persons (83.4% vs.
66.6%, p,0.001). Among all cases, 18,540 (50.3%) were foreign-
born attributable to reactivation TB; 3,611 (9.8%) were foreign-
born attributable to recent transmission; 9,723 (26.4%) were U.S.-
born attributable to reactivation; 4,871 (13.2%) were U.S.-born
and attributable to recent transmission (Figure 1).
Mexico, the Philippines, and Viet Nam, were the top three
countries of origin, accounting for 23.7%, 11.7%, and 8.7% of
total foreign-born cases in the U.S., respectively (Table 1).
Foreign-born persons from Bangladesh had the highest proportion
of TB cases attributed to reactivation TB (97.6%) followed by
India (95.2%) and Myanmar (93.3%) (Table 1).
Figure 1. Tuberculosis attributed to recent transmission versus
reactivation of remote tuberculosis infection by nativity,
United States 2005–2009. Legend: Solid black = Foreign-born,
reactivation TB Solid white = U.S.-born, reactivation TB Black back-
ground with grid = Foreign-born, recent transmission TB White back-
ground with grid = U.S.-born, recent transmission TB.
doi:10.1371/journal.pone.0027405.g001
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Compared to foreign-born persons with TB from countries with
TB incidence of ,20 cases per 100,000, the odds of having
reactivation TB were greatest among persons from countries with
a TB incidence . = 150/100,000 (OR = 1.3; 95% CI = 1.2, 1.4).)
(Table 2). Age at arrival in the United States was associated with
reactivation TB. Compared to foreign-born persons less than 14
years of age, the odds of reactivation TB was 2.0 (95% CI: 1.9, 2.2)
times more likely among those aged 15–24 years at arrival; 2.5
Table 1. Top twenty-five countries of origin with the highest proportion of reactivation TB among foreign-born persons
diagnosed with TB in United States, 2005–2009*.
Reactivation TB Recent TB Transmission Total
n (%) n (%) n (%)1
Country
Bangladesh 120 (97.6) 3 (2.4) 123 (0.6)
India 1,503 (95.2) 76 (4.8) 1,579 (7.1)
Myanmar 166 (93.3) 12 (6.7) 178 (0.8)
Pakistan 215 (91.1) 21 (8.9) 236 (1.1)
Kenya 226 (90.4) 24 (9.6) 250 (1.1)
Indonesia 122 (90.4) 13 (9.6) 135 (0.6)
Nepal 159 (90.3) 17 (9.7) 176 (0.8)
El Salvador 360 (88.9) 45 (11.1) 405 (1.8)
Cambodia 252 (88.4) 33 (11.6) 285 (1.3)
Republic of South Korea 455 (88.2) 61 (11.8) 516 (2.3)
Honduras 397 (87.8) 55 (12.2) 452 (2.0)
Thailand 131 (86.8) 20 (13.2) 151 (0.7)
Viet Nam 1,661 (86.7) 255 (13.3) 1,916 (8.7)
Haiti 340 (85.2) 59 (14.8) 399 (1.8)
People’s Republic of China 990 (84.7) 179 (15.3) 1,169 (5.3)
Peru 313 (83.0) 64 (17.0) 377 (1.7)
Guatemala 570 (82.8) 118 (17.2) 688 (3.1)
Mexico 4,289 (82.0) 943 (18.0) 5,232 (23.7)
Ethiopia 457 (81.3) 105 (18.7) 562 (2.5)
Laos 203 (81.2) 47 (18.8) 250 (1.1)
Somalia 393 (78.6) 107 (21.4) 500 (2.3)
Nigeria 95 (77.2) 17 (13.8) 123 (0.9)
The Philippines 1,959 (75.9) 623 (24.1) 2,582 (11.7)
Ecuador 243 (70.6) 101 (29.4) 344 (1.6)
Dominican Republic 124 (60.5) 81 (39.5) 205 (0.9)
All Foreign-born 18,540 (83.7) 3,611 (16.3) 22,151
*Among countries with at least 100 reported cases.
1Column percent.
doi:10.1371/journal.pone.0027405.t001
Table 2. Proportion of reactivation TB among foreign-born TB cases by estimated annual TB incidence in the country of origin,
United States 2005–2009.
Reactivation TB Recent TB Transmission Total Odds Ratio (95% CI)
n (%) n (%) n (%)1
Estimated TB Incidence2
,20 4,788 (82.0) 1,060 (18.0) 5,848 (26.4) referent - -
20 to 149 4,792 (83.2) 967 (16.8) 5,759 (26.0) 1.1 (1.0, 1.2)
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(95% CI: 2.3, 2.7) times more likely among those aged 25–44
years; 2.8 (95% CI: 2.5, 3.1) times more likely among those aged
45–64 years, and 3.2 (95%CI: 2.7, 3.8) times more likely among
those .65 years (Table 3). Less time in the U.S. prior to TB
diagnosis was also associated with increased odds of reactivation
TB among foreign-born persons (Table 4). Compared to foreign-
born persons in the U.S. more than 5 years, the odds of
reactivation TB were 1.3 (95% CI: 1.2, 1.4) times higher among
those in the U.S. for less than 2 years, and 1.1 (95% CI 1.0, 1.3)
times higher among those in the U.S for 2 to 5 years before TB
diagnosis (Table 4).
Discussion
Foreign-born persons account for the majority of cases reported
in the U.S. [1] and approximately 4 out of 5 of these cases can be
attributed to reactivation TB. Cases of reactivation TB among the
foreign-born account for half of all cases and represent the single
largest challenge to achieving TB elimination in the U.S. This
national estimate is consistent with numerous smaller, more
localized studies in the United States [16–19,32] and in Europe
[33,34]. This evidence suggests that the majority of reported TB
cases are due LTBI acquired prior to entering the U.S. and
subsequent reactivation of TB among foreign-born persons, either
occurring soon before or soon after entering the U.S. Therefore,
addressing the burden of LTBI in persons entering the United
States through either LTBI testing and treatment or through
prevention of LTBI will be essential for TB elimination. While
immigration screening programs have been enhanced to improve
detection and treatment of tuberculosis disease in this population,
the primary purpose is to identify active TB disease, not LTBI
testing and treatment among adults [35].
Currently, there is no policy to test for LTBI among foreign-
born adults prior to or during their entry process to the U.S. [36].
The only persons that are tested for LTBI during the immigration
process are children aged 2–14 years from countries with TB
incidence exceeding 20/100,000. The primary purpose of this
testing is to identify children who need more complete evaluation
for active TB disease, not to identify and treat patients with LTBI.
For foreign-born persons who already reside in the United States,
current guidelines recommend LTBI testing only for persons who
have been in the U.S. ,5 years [37].
To meet the goal of TB elimination in the U.S., (1 case per
1,000,000 persons per year), the burden of LTBI among the
foreign-born will have to be reduced [3,13]. There are two general
approaches to doing this: 1) find and treat foreign-born persons
with LTBI (either before or after they enter the United States); or
2) prevent LTBI in foreign-born persons by improving TB control
in their country of origin, thereby reducing TB transmission and
the risk of TB infection [38].
In addition to testing for LTBI, success also requires initiating
and completing treatment of persons with LTBI. The current
standard therapy for LTBI, isonaizid (INH), can reduce the risk of
progression from LTBI to active TB by as much as 90% if taken
daily for 9 months [39]. Unfortunately completion rates for 9
months of INH are poor, but vary under programmatic
conditions; with many programs reporting less than 50%
completion [39]. A new regimen, a once weekly dose of INH
and rifapentine taken for 12 weeks (3HP), has the potential to
improve adherence and completion of therapy [40,41] and
Table 3. Proportion of reactivation TB among foreign-born TB cases by age at tuberculosis diagnosis, United States 2005–2009.
Reactivation TB
Recent TB
Transmission Total Odds Ratio (95% CI)
n (%) n (%) n (%)1
Age at tuberculosis diagnosis (in years)
0–14 141 (78.3) 39 (21.7) 180 (0.8) referent - -
15–24 2,697 (82.0) 594 (18.0) 3,291 (14.9) 2.1 (1.8, 2.5)
25–44 7,546 (84.1) 1,425 (15.9) 8,968 (40.5) 2.3 (2.0, 2.7)
45–64 4,620 (82.3) 992 (17.7) 5,612 (25.3) 1.9 (1.7, 2.3)
$65 3,536 (86.3) 561 (15.5) 4,100 (18.5) 4.5 (3.7, 5.2)
1Column percent.
doi:10.1371/journal.pone.0027405.t003




Transmission Total Odds Ratio2 (95% CI)
n (%) n (%) n (%)1
Time in the United States prior to TB Diagnosis
Less than 2 years 6,575 (85.7) 1,110 (14.5) 7,675 (34.6) 1.3 (1.2, 1.4)
2 to 5 years 2,795 (84.0) 531 (16.0) 3,326 (15.0) 1.1 (1.0, 1.3)
Greater than 5 years 9,170 (82.2) 1,980 (17.8) 11,150 (50.3) referent - -
1Column percent.
2Comparing nonclustered to clustered.
doi:10.1371/journal.pone.0027405.t004
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perhaps may influence the intent to treat LTBI among foreign-
born persons. These regimens are likely to be efficacious, as only
9.4% (n = 1,748) of all foreign-born person with reactivation TB
had isolates that were resistant to INH, rifampicin, or both during
the 5 year study period.
This study does have some important limitations. First, isolate
submission to the U.S. National TB Genotyping Service (NTGS) is
voluntary, thus the database, although large, did not contain all
reported culture-positive TB cases for the study period. However
the potential for systematic bias due to voluntary isolate
submission is unlikely, as we found no statistical difference with
regards to clinical, demographic, or social factor between TB cases
with and those without genotyping results (data not shown).
Second, spatial and genotype clustering serves only as a proxy for
differentiating recent TB transmission and reactivation TB in the
absence of detailed data on interpersonal connections between
cases. It is possible that recent immigrants who became infected
with the same genotype elsewhere and resettle in the same
neighborhood in the U.S. could subsequently develop TB after
resettlement and falsely be considered recent TB transmission.
Third, although spoligotyping and 12-locus MIRU-VNTR have
good discriminatory power, these methods may not provide the
resolution necessary to differentiate evolutionarily close strains
[42–43]. Moreover, deriving the portion of reactivation TB among
foreign-born persons based on genotyping methods is dependent
on the genetic diversity of strains circulating in different regions of
the world. The introduction of a more specific expanded panel of
24 MIRU-VNTR loci in 2009 to NTGS may reduce this
misclassification in the future. It is important to note that each
of these limitations would most likely underestimate the true
proportion of foreign-born persons attributed to reactivation TB,
further emphasizing the importance of reactivation TB in the
United States.
At present, the high burden of reactivation TB is caused
primarily by 1) the lack of LTBI screening among adult
immigrants, both prior to arrival and after taking up residence,
and 2) low initiation and completion rates for LTBI treatment
[37]; and 3) ongoing high rates of TB disease (and therefore
infection) in many countries from which foreign-born persons
come to the United States. To reduce the incidence of TB among
foreign-born persons, efforts to increase testing and for those
testing positive both initiation and completion of therapy must be
applied both for those planning to immigrate and those already
residing in the U.S., and thus needs to be combined with efforts to
improve global TB control. While universal testing and treatment
for LTBI among all foreign-born persons would not be cost-
effective, as most would not progress to active TB disease [30],
targeted, cost-effective testing strategies need to be developed that
account for incidence in country of origin, travel, and medical
history [44–45]. Given the low specificity of TST, the use of
interferon-gamma release assays (IGRA) might be a more suitable
screening tool in these situations [46,47]. Studies to measure the
efficacy and cost-benefit of these programs should include foreign-
born populations residing in the U.S. and those planning to
immigrate, as failure to detect and treat LTBI in the country of
origin can have costs in the U.S [46]. Strategies for completion of
LTBI treatment among foreign-born persons and potential
immigrants also need to be developed, which might include non-
traditional DOT strategies, incentives, shortened treatment
regimens, and social service support. Operations research would
be needed to identify the strategy that is most feasible, effective,
and acceptable.
Finally, efforts to improve global TB control are needed. TB
incidence remains very high in many countries, causing a very
high proportion of persons living in those countries to develop
LTBI. If TB incidence could be brought down, LTBI could be
prevented in many persons. All of these efforts combined will be
needed to substantially impact the burden of LTBI in foreign-born
persons entering the United States. Without addressing that LTBI
burden, it will be impossible to achieve our goal of TB elimination.
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